Rafael Holdings, Inc. (RFL) Stock Price & Analysis
Rafael Holdings, Inc. (RFL) closed at USD 1.28 on Thursday, October 22, 2026, down 1.54% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1.28; the Oct 22, 2026 session ranged USD 1.25–1.29 on volume of 37,054 shares. Market capitalization is —, with a 52-week range of USD 1.12–3.96 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RFL.md
Key facts (RFL)
- Last four reported quarters (through Apr 30, 2026): revenue $980K, net income -$20.7M (-2117.2% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold RFL (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y -5.9% vs S&P 500 +14.9%; 5Y -95.8% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD —, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RFL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $802K | $410K | $279K | $637K | $917K | $980K |
| Gross profit | -$2.4M | -$3.1M | — | $483K | — | — |
| Operating income | -$28.2M | -$60.5M | -$15.0M | -$103M | -$29.2M | -$36.4M |
| Net income | -$23.1M | -$125M | -$1.9M | -$34.4M | -$30.5M | -$20.7M |
| EPS (diluted) | -$1.47 | -$6.22 | -$0.08 | -$1.45 | -$1.04 | — |
| Free cash flow | -$15.8M | -$26.1M | — | -$7.9M | -$18.9M | — |
| Gross margin | -295.1% | -753.4% | — | 75.8% | — | — |
| Operating margin | -3516.1% | -14750.5% | -5391.8% | -16111.0% | -3179.8% | -3717.2% |
| Net margin | -2875.4% | -30404.4% | -672.4% | -5401.9% | -3328.2% | -2117.2% |
| Revenue growth | -83.7% | -48.9% | -32.0% | +128.3% | +44.0% | — |
| Cash + short-term investments | $7.9M | $63.2M | $79.2M | $65.9M | — | — |
| Total debt | — | — | — | $73K | $78K | — |
Fiscal years end Jul. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Apr 30, 2026) (RFL)
Superinvestors (SEC 13F-HR, Q2 2026) (RFL)
1 of 80 tracked investors hold RFL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Kahn Brothers | Kahn Brothers Group | 0.01% | $73K | Unchanged |
Total return (dividends reinvested) (RFL)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -5.9% | -95.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -5.9% | -46.9% |
| Volatility (annualized) | 87.1% | 86.4% |
| Max drawdown | -66.1% (Jul 2026→Oct 2026) | -96.2% (Oct 2021→Jan 2026) |
RFL revenue by product line (quarter ended Apr 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product Revenue | $89,000 | 49.7% | -63.4% |
| Rental Third Party | $60,000 | 33.5% | +22.4% |
| Rental Related Party | $30,000 | 16.8% | +7.1% |
| Total revenue | $179,000 | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RFL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Rafael Medical Devices | “to manufacture our, the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates.” |
| Partner | Farber Partners | “Since then, we have sought partners for Farber programs and has entered into a license agreement for one of its technologies” |
| Partner | Medical Devices | “Medical Devices or their collaborators or us could cause substantial liabilities and could limit commercialization of any medical devices” |
| Competitor | Johnson & Johnson (JNJ) | “competition from Actelion, a subsidiary of Johnson & Johnson , Zevra Therapeutics, Inc., Mandos Health, Azafaros, and IntraBio, among” |
Quoted from the company's 10-K filed Oct 29, 2025.
RFL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
RFL options: expected move
Options price a move of about ±97.3% (±$1.25) by Nov 20, 2026, which includes earnings on Oct 28, 2026. Over the last 8 reports the stock moved ±8.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 160.6% | ±97.3% |
| Feb 19, 2027 | 119 | 117.6% | ±109.4% |
30-day implied volatility 116.2% vs 139.4% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 1.28 |
|---|---|
| Change | ▼ 1.54% (down) |
| Previous Close | USD 1.28 |
| Open | USD 1.28 |
| Day Range | USD 1.25 – 1.29 |
| 52-Week Range | USD 1.12 – 3.96 |
| Volume | 37,054 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (RFL)
Nexqual's technical model rates RFL "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.3 (oversold) |
| vs SMA50 | Below (USD 1.92) |
| MACD | -0.18 (negative) |
Earnings (RFL)
| Next Earnings Date | 2026-10-28 |
|---|
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (RFL)
| Total Revenue | $980,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -50.60% |
| Gross Margin | +95.10% |
| Operating Margin | -3837.99% |
| Profit Margin | +0.00% |
| ROE | -37.59% |
| Debt / Equity | 0.01 |
| Current Ratio | 3.16 |
| Total Cash | $30.50M |
| Total Debt | $610,000 |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Ownership (RFL)
| Insider Ownership | +38.23% |
|---|---|
| Institutional Ownership | +8.08% |
| Shares Outstanding | 51.21M |
| Float | 31.77M |
| Short % of Float | +3.65% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From Rafael Holdings, Inc.'s Latest SEC 10-K Filing (filed 2025-10-29)
Key Strengths & Strategy (as disclosed to the SEC)
- On December 11, 2024, Rafael Medical Devices received a substantial equivalence determination for the VECTR System from the Food and Drug Administration ("FDA") in response to Rafael Medical Devices' 510(k) premarket notification.
- The FDA's clearance of the VECTR System is for use in minimally invasive ligament or fascia release surgeries, such as carpal tunnel release in the wrist and cubital tunnel release in the elbow.
- If Trappsol® Cyclo™ were to be approved under an orphan-designated indication, it would provide Cyclo with the exclusive right to sell Trappsol® Cyclo™ for the treatment of NPC1 for seven years in the United States following FDA drug approval, and will provide 10 years of market exclusivity in Europe following EMA regulatory approval.
- The voucher, subject to meeting eligibility requirements and current statutory deadlines, could be awarded to the sponsor of a designated rare pediatric disease product application in the event that its New Drug Application ("NDA") or Biologics License Application ("BLA") receives FDA approval.
Partnerships
- Barer's majority owned subsidiary, Farber Partners, LLC ("Farber"), was formed around one such agreement with Princeton University's Office of Technology Licensing ("Princeton") for technology from the laboratory of Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HBB | Hamilton Beach Brands Holding C | USD 33.39 | ▲ 0.15% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 3.83 | ▲ 5.51% |
| APYX | Apyx Medical Corporation | USD 2.41 | ▼ 3.98% |
| ZDGE | Zedge, Inc. | USD 2.8 | ▲ 0.72% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▼ 50% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt